Figure 12.

ROS‐responsive and pH‐responsive nanocarrier‐based nanomedicines for the treatment of FNDs. a) Schematic illustration of the design of ROS‐responsive drug carrier polymer targeting the cell membrane, inhibiting necroptosis, and depleting ROS for retinal ischemia‐reperfusion injury. Reproduced with permission.^{[ 218 ]} Copyright 2022, American Chemical Society. b) Schematic illustration of mitochondria‐targeted ROS‐responsive liposomal quercetin attenuating retinal ischemia‐reperfusion injury via regulating SIRT1/FOXO3A and p38 MAPK signaling pathways. Reproduced under the terms of the CC‐BY.^{[ 136 ]} Copyright 2022, The Authors, published by Wiley Periodicals LLC. c) Schematic illustration of pH‐responsive polymer PACD promoting cytosolic siRNA release in retinal cells and abrogating hypoxia‐induced RNV. Reproduced with permission.^{[ 242 ]} Copyright 2024, Elsevier. d) Schematic illustration of a core‐shell delivery nanosystem combining DOPE as the outer shell, lipid bilayer as the inner shell, and dendrimers loaded with nuclear localization signal as the inner core. Reproduced with permission.^{[ 243 ]} Copyright 2021, Elsevier.